Business
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":" MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced significant effects of PRP against the tumor microenvironment and pre-metastatic niche has been reported by the Company’s joint researcher, Mrs. Belén Toledo Cutillas MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén. Treatment with PRP was shown to have a favorable impact inhibiting, slowing, or reversing tumor development by acting as an anti-tumor agent, decreasing tumor cell proliferation, developing a non-malignant phenotype (observable characteristics) and promoting cell adhesion (sticking close to one another) and differentiation (cell specialization rather than stem cell like). It was concluded that PRP could have a significant impact on the tumor microenvironment as a potential clinical application. PRP is a combination of the two proenzymes trypsinogen and chymotrypsinogen.\n\nCancer remains one of the leading causes of death, globally. Despite recent advances in understanding its molecular and genetic basis, more than one third of those affected die each year from cancer. These alarming results are mainly attributed to current therapies not fully effective against cancer cells which may develop drug resistance, leading to recurrence and metastasis, causing more than 90% of cancer-related deaths. According to Mrs. Cutillas, “This is why we need to find better and more effective therapeutic strategies”. She explains that tumor formation is influenced by two factors, genetic changes in tumor cells and the rearrangement of components of the tumor microenvironment. In recent years, cancer research has focused on the tumor microenvironment.\n\nNumerous assays, in vitro and in vivo studies, were conducted by Mrs. Cutillas confirming that PRP appears to have an anti-tumor effect and can act selectively against specific tumor elements, without affecting the non-tumor microenvironment and preventing its malignification (i.e., the process of making malignant).\n\nDr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer said, “The work undertaken by Mrs Cutillas highlights the significant potential applications of PRP in a clinical setting, specif...